# A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator

> **NCT00631007** · PHASE2 · COMPLETED · sponsor: **InteKrin Therapeutics, Inc.** · enrollment: 367 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** INT131 besylate
- **DRUG:** Pioglitazone HCl
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00631007
- **Lead sponsor:** InteKrin Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-08
- **Final completion:** 2009-09
- **Target enrollment:** 367 (ACTUAL)
- **Last updated:** 2010-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00631007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00631007, "A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00631007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*